Tetrabenazine therapy of pediatric hyperkinetic movement disorders.
Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug-induced Parkinsonism.
Jain
Samay
S
Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. jains@upmc.edu
Greene
Paul E
PE
Frucht
Steven J
SJ
D000293:Adolescent; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy*; D007223:Infant; D008297:Male; D010372:Pediatrics; D012189:Retrospective Studies; D013747:Tetrabenazine / Q000627:therapeutic use*
D018726:Anti-Dyskinesia Agents; D013747:Tetrabenazine